20 Microns, a leading material science company, closed FY25 with a strong revenue momentum. For FY25, the company reported revenue growth of 17%. This was its highest growth rate in ten years, if you ignore the Covid rebound year, FY22, when topline grew 27% after a 9% contraction the previous year.
In fact, 20 Microns has among the most consistent growth record amongst listed companies in India. ‘The company has delivered a topline growth > 8% in 8 of the last ten years. The two exceptions: one in the Covid phase and the other in FY16. In other words, 20Microns.
Its profitability performance is also remarkably steady. 20Microns has delivered EBITDA growth in 8 of the last 10 years. The exceptions – FY20 and FY21, where Covid related supply chain disruptions played a role, A point worth noting is that the company has declared double digit EBITDA margin in each of the last 10 years, indicating consistency of business model.
To download the detailed investor guide prepared by us for Q4FY25, Click here.
PS: Wisdom-IR is investor relations advisor to 20 Microns Limited. In case you have any queries for the management, you can address them to us.
About the company: 20 Microns Limited is a pioneering material science firm specializing in the advanced processing and application of industrial minerals, delivering high-performance solutions for sectors such as coatings, polymers, adhesives, and advanced ceramics. Leveraging deep expertise in particle engineering and surface modification, the company transforms raw minerals like barytes, calcium carbonate, and talc into functional additives that enhance material properties such as strength, durability, and dispersion. With a strong emphasis on innovation, 20 Microns Limited invests in cutting-edge R&D to develop sustainable, next-generation mineral solutions that meet evolving industry demands. By combining material science excellence with precision manufacturing, the company serves as a key enabler for industries seeking optimized performance, efficiency, and eco-friendly alternatives in their formulations.